Newsfeeds Archive - Page 7 of 696

1 minute read

News

Sunrise New Energy Announces Patent Application For Multivariable Particle Size Control System For Graphite Micropowder Production Accepted By The National Intellectual Property Bureau

December 18, 10:34 AM

Sunrise New Energy Co., Ltd. ("Sunrise", the "Company", "we" or "our") (NASDAQ:EPOW), today announced that the patent application for the invention titled "Multivariable

EPOW

2 minute read

Cosmos Health Announces Open Market Stock Purchases By The CEO; Mr Greg Siokas, Intends To Purchase An Aggregate Of Up To $3M In Common Shares Of The Company In The Open Market Through December 31, 2024

By Happy Mohamed

December 18, 10:19 AM

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of

COSM

2 minute read

Frontdoor Promotes Evan Iverson To SVP & Chief Operations Officer, Effective Jan 1 2024

By Happy Mohamed

December 18, 10:15 AM

Newly created positions of Chief Revenue Officer and Chief Operations Officer to further streamline and strengthen the American Home Shield and Frontdoor brands Frontdoor, Inc. (NASDAQ:FTDR), the nation's

FTDR

1 minute read

Castor Maritime Inc. Announces The Sale Of The M/V Magic Orion For $17.4M With An Expected Net Gain Of $2M And The Completion Of The Sale Of The M/V Magic Argo

By Happy Mohamed

December 18, 10:14 AM

Castor Maritime Inc. (NASDAQ:CTRM), ("Castor" or the "Company"), a diversified global shipping company, announces that on December 7, 2023, the Company entered into an agreement with an unaffiliated

CTRM

2 minute read

News

CrowdStrike And Optiv Surpass $1B In Sales Milestone In Sales Of Its AI-Native CrowdStrike Falcon Platform Through The CrowdStrike Accelerate Partner Program

By Happy Mohamed

December 18, 10:11 AM

Premier partnership surpasses key milestone, modernizing and consolidating cybersecurity for thousands of organizations CrowdStrike (NASDAQ:CRWD) announced that Optiv, the cyber advisory and solutions leader,

CRWD

2 minute read

Coupang To Acquire The Business And Assets Of Farfetch Holdings; Agreement Gives Farfetch Access To $500M Of Capital To Continue Providing Exclusive Brands And Boutiques With Bespoke Cutting-Edge Technology; Financial Terms Of The Transaction Were Not…

By Happy Mohamed

December 18, 10:07 AM

Coupang, Inc. (NYSE:CPNG), a leading global retailer, today announced plans to acquire the business and assets of Farfetch Holdings plc, a top online luxury company. This acquisition positions Coupang as a leader in the $400 billion global personal luxury goods segment.

CPNG

1 minute read

FDA
News

Sysco And iFoodDS To Explore Flexible Network Solutions For FSMA 204 Food Traceability Rule Compliance

By Happy Mohamed

December 18, 10:05 AM

Sysco Corporation (NYSE:SYY), and iFoodDS announced a proof-of-concept project to explore solutions that enable Sysco and its diverse supplier base to capture, store, and share data required by the U.S. Food and Drug

SYY

4 minute read

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B And MTAP Deletions

By Happy Mohamed

December 18, 10:04 AM

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle

CYCC

5 minute read

FDA Approves Arcutis’ ZORYVE Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older

By Happy Mohamed

December 16, 7:41 PM

ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use ZORYVE foam

ARQT

5 minute read

FDA Approves Expanded Indication For KEYTRUDA Plus Padcev For The First-Line Treatment Of Adult Patients With Locally Advanced Or Metastatic Urothelial Cancer

By Happy Mohamed

December 16, 7:38 PM

Approval is based on results from the Phase 3 KEYNOTE-A39 trial, which demonstrated a superior overall survival benefit with KEYTRUDA plus Padcev versus platinum-based chemotherapy (gemcitabine plus cisplatin or

MRK